1. Herrman W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE: Effet d'un steroide antiprogesterone chez la femme interruption du cycle menstruel et de la grossesse au debut. C R Acad Sci Paris 294: 933, 1982
2. Elger W, Beier S, Chawalisz K, Fähnrich M, Hasan SH, Henderson D, Neef G, Rohde R: Studies on the mechanisms of action of progesterone antagonists. J Steroid Biochem 25: 835–845, 1986
3. Maudelonde T, Romieu G, Ulmann A, Pujol H, Grenier J, Khalaf S, Cavalie G, Rochefort H: First clinical trial on the use of the antiprogestin RU 486 in advanced breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents. Raven Press, New York, 1987, pp 55–59
4. Gill PG, Vignon F, Bardon S, Derocq D, Rochfort H: Difference between R5020 and the antiprogestin RU 486 in antiproliferative effects on human breast cancer cells. Breast Cancer Res Treat 10: 37–45, 1987
5. Bakker GH, Setyono-Han B, de Jong FH, Klijn JGM: Mifepriston in treatment of experimental breast cancer in rats. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents. Raven Press, New York, 1987, pp 39–48